Tirzepatide constipation symptom guide

Tirzepatide constipation: current Zepbound and Mounjaro rates

Review constipation during tirzepatide care using current Zepbound and Mounjaro labels, including product-specific trial rates, severe-symptom red flags, medication review, compounded-product distinctions, and questions for the prescriber.

Educational guideUpdated August 3, 2026

A label-first response to constipation during tirzepatide care

Identify the exact product: Zepbound, Mounjaro, or a patient-specific compounded tirzepatide prescription, plus its indication, presentation, pharmacy, and current label.

Describe the bowel change: frequency, stool hardness, straining, incomplete emptying, bloating, pain, and whether stool and gas still pass.

Record onset, duration, severity, fluid and food intake, urine output, and timing relative to treatment, a clinician-directed change, refill, illness, travel, or another medicine.

Contact the prescriber before changing treatment or adding a laxative, fiber product, magnesium product, enema, suppository, or supplement.

Use prompt in-person care for severe abdominal, obstruction-like, dehydration, bleeding, neurologic, or other emergency warning signs.

Direct answer

Constipation is a common adverse reaction with tirzepatide, but rates are product- and study-specific. In pooled Zepbound weight-reduction trials, a grouped category that included constipation and hard stools occurred in 17%, 14%, and 11% of participants across the three listed Zepbound groups versus 5% with placebo. In pooled Mounjaro placebo-controlled trials in adults with type 2 diabetes, constipation occurred in 6%, 6%, and 7% across the three listed Mounjaro groups versus 1% with placebo. These separate tables are not a head-to-head comparison and do not establish a rate for patient-specific compounded tirzepatide. Contact the prescriber for new, persistent, worsening, painful, or function-limiting constipation. Severe or persistent abdominal pain, repeated vomiting, marked abdominal swelling, inability to pass stool or gas, blood or black stool, fainting, confusion, or inability to keep fluids down needs prompt in-person assessment.

Current label answer

Zepbound and Mounjaro publish different product-specific constipation tables

The current Zepbound and Mounjaro prescribing information was updated April 22, 2026. Both branded products contain tirzepatide for subcutaneous injection, but their labeled uses and trial populations differ. In pooled Zepbound Study 1 and Study 2 data for adults with obesity or overweight, a grouped category that includes constipation and hard stools occurred in 5% of placebo participants and 17%, 14%, and 11% of participants across the three listed Zepbound groups. In pooled Mounjaro placebo-controlled trials in adults with type 2 diabetes, constipation occurred in 1% of placebo participants and 6%, 6%, and 7% across the three listed Mounjaro groups.

Keep each percentage tied to its product, study population, and label table; the two tables are not a randomized head-to-head comparison.
The Zepbound percentages represent a grouped category that includes constipation and hard stools, not a hard-stool-only rate.
Group-level trial percentages do not predict one person’s severity, timing, duration, or response and should not be transferred to a patient-specific compounded preparation.

Symptom pattern and urgency

Routine bowel changes and obstruction-like symptoms need different pathways

Constipation can mean fewer bowel movements, harder stools, straining, incomplete emptying, or a meaningful change from a person’s usual pattern. The labels also list postmarketing reports of ileus, intestinal obstruction, and severe constipation including fecal impaction. Because voluntary postmarketing reports come from a population of uncertain size, they do not provide a frequency or prove tirzepatide caused an individual event. They do support taking severe, progressive, or obstruction-like symptoms seriously rather than assuming every bowel change is routine.

Record the last bowel movement, stool consistency, ability to pass gas, abdominal swelling, pain location and severity, nausea or vomiting, fever, bleeding, food and fluid intake, and urine output.
Contact the prescriber for a persistent or worsening change, painful bowel movements, marked straining, symptoms after a refill or clinician-directed change, or constipation that affects eating, drinking, sleep, work, or diabetes care.
Seek prompt in-person assessment for severe or persistent abdominal pain, repeated vomiting, marked swelling or a rigid abdomen, inability to pass stool or gas, blood or black stool, fainting, confusion, severe weakness, or inability to keep fluids down.

Medication and medical review

Other medicines, low intake, and prior bowel conditions may change the assessment

A bowel-pattern change may overlap with reduced food or fluid intake, travel, illness, pregnancy, a prior gastrointestinal condition, or another medicine. Opioid pain medicines, iron, some antacids, anticholinergic medicines, some antidepressants, antihistamines, and other products can contribute to constipation for some people. A clinician should review the full pattern instead of assuming the injection is the only possible cause or automatically recommending the same remedy to everyone.

Share prior constipation, bowel obstruction or surgery, hernia, severe gastroparesis, pelvic-floor problems, kidney or heart disease, pregnancy possibility, recent illness, and meaningful changes in food, fluid, activity, or weight.
List every prescription, over-the-counter medicine, vitamin, mineral, fiber product, laxative, antacid, pain medicine, antihistamine, supplement, alcohol product, and cannabis product.
Do not combine laxatives, use repeated enemas, start a “detox,” or follow a forum clean-out plan without individualized clinician or pharmacist guidance.

Product identity and evidence boundary

Branded trial rates do not establish a compounded-tirzepatide constipation rate

Zepbound and Mounjaro are FDA-approved finished tirzepatide products with product-specific indications, presentations, instructions, and evidence. A patient-specific compounded tirzepatide preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, container, labeling, storage, and beyond-use date. Constipation after a refill or product change should prompt verification of the exact label and pharmacy rather than an assumption that every pen or vial is interchangeable.

Bring the product name, indication, presentation, strength or concentration, manufacturer or dispensing pharmacy, prescriber, refill or lot details, storage history, and a photo of the current label.
Contact the responsible prescriber before skipping, repeating, stopping, restarting, splitting, increasing, decreasing, or otherwise changing a tirzepatide prescription.
Avoid research-use products, unlabeled vials, counterfeit pens, copied syringe or bowel-cleanout charts, and sellers that provide tirzepatide without prescription-first clinician review.

Follow-up plan

A safe plan is individualized and includes a clear escalation pathway

For non-emergency constipation, the prescriber can review symptoms, hydration and nutrition, other medicines, medical history, and the exact tirzepatide product before deciding whether examination, testing, a bowel-management plan, or a treatment change is appropriate. Generic advice to drink more, add fiber, or take a laxative may not fit someone with vomiting, severe pain, obstruction-like symptoms, fluid restrictions, kidney disease, pregnancy, or medication interactions.

Ask which food, fluid, activity, or bowel-product steps fit the individual medical history and when lack of improvement should trigger reassessment.
Ask whether glucose, kidney function, hydration, pregnancy, abdominal examination, imaging, or another evaluation is relevant to the actual symptom pattern.
Know whether to use routine messaging, same-day clinical guidance, urgent care, or emergency services before symptoms worsen.

Patient safety checklist

Questions to ask about constipation during tirzepatide treatment

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Which exact product am I using: Zepbound, Mounjaro, or a patient-specific compounded tirzepatide prescription, and what indication, presentation, and current label apply?

✓

What changed from my usual bowel pattern, when did it start, when was my last bowel movement, and can I still pass gas?

✓

Do I have severe or persistent pain, marked abdominal swelling, repeated vomiting, fever, blood or black stool, dizziness, fainting, confusion, reduced urination, or inability to keep fluids down?

✓

Did symptoms follow treatment, a clinician-directed change, a refill, illness, travel, reduced intake, another medicine, or a new supplement?

✓

Could opioids, iron, antacids, antihistamines, antidepressants, anticholinergic medicines, laxatives, fiber, magnesium, or another product change the assessment?

✓

Do prior bowel obstruction or surgery, severe gastroparesis, hernia, kidney or heart disease, pregnancy possibility, or another condition change the safest plan?

✓

Which individualized food, fluid, activity, or bowel-product steps are appropriate, and when should I report that they are not working?

✓

Who should I contact before the next treatment or refill, and which symptoms should bypass messaging for urgent or emergency assessment?

FAQs

Short answers for patients

How common is constipation with tirzepatide?

Rates depend on the exact product and trial. Current Zepbound weight-reduction labeling reports a grouped constipation-and-hard-stool category in 17%, 14%, and 11% of participants across the three listed groups versus 5% with placebo. Current Mounjaro type 2 diabetes labeling reports constipation in 6%, 6%, and 7% across its three listed groups versus 1% with placebo. These separate tables are not a head-to-head comparison or universal personal-risk estimate.

How long does tirzepatide constipation last?

Current Zepbound and Mounjaro labels do not provide one constipation duration for every patient. Record the actual onset, duration, severity, exact product, bowel pattern, fluid and food intake, other symptoms, refill or treatment-change timing, and other medicines. Contact the prescriber for persistent, painful, recurrent, worsening, or function-limiting symptoms.

Why are Zepbound and Mounjaro constipation rates different?

They contain the same active ingredient but have different labeled uses, trial populations, and adverse-reaction tables. Zepbound also uses a grouped category that includes constipation and hard stools. The percentages cannot show that one product causes more constipation because the tables do not come from one randomized head-to-head comparison.

Do branded tirzepatide constipation rates apply to compounded tirzepatide?

No. A patient-specific compounded preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, presentation, labeling, storage, and beyond-use date. Zepbound and Mounjaro trial rates do not establish a constipation incidence or product quality for a compounded preparation.

Should I skip tirzepatide if I am constipated?

Do not skip, repeat, stop, restart, split, or change a tirzepatide prescription based on generic online advice. Contact the responsible prescriber with the bowel pattern, other symptoms, intake, medicines, and product details before the next treatment decision. Urgent warning signs require in-person assessment.

Can I take a laxative with tirzepatide?

Ask the responsible clinician or pharmacist before adding or combining laxatives. Severe pain, vomiting, inability to pass gas, marked swelling, bleeding, kidney or heart disease, pregnancy, fluid restrictions, other medicines, and the exact cause of constipation can change which options are appropriate or whether in-person assessment is needed first.

When is constipation during tirzepatide care urgent?

Seek prompt in-person care for severe or persistent abdominal pain, repeated vomiting, marked abdominal swelling or rigidity, inability to pass stool or gas, blood or black stool, fainting, confusion, severe weakness, markedly reduced urination, or inability to keep fluids down.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current ZEPBOUND prescribing information — updated April 22, 2026 DailyMed: Current MOUNJARO prescribing information — updated April 22, 2026 MedlinePlus: Tirzepatide injection drug information — revised February 15, 2026 MedlinePlus: Constipation FDA: Compounding and the FDA — Questions and Answers FDA MedWatch: Report a serious problem with a medical product Peptide12: Compounded tirzepatide injection Peptide12: Zepbound Peptide12: Mounjaro Peptide12: GLP-1 constipation Peptide12: Tirzepatide nausea Peptide12: GLP-1 kidney and dehydration risk Peptide12: Constipation medicines and peptide care Peptide12: When to message your clinician Peptide12: How online peptide therapy works